vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and IT TECH PACKAGING, INC. (ITP). Click either name above to swap in a different company.
IT TECH PACKAGING, INC. is the larger business by last-quarter revenue ($25.6M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -5.7%, a 4.8% gap on every dollar of revenue. On growth, IT TECH PACKAGING, INC. posted the faster year-over-year revenue change (2.1% vs -25.7%). IT TECH PACKAGING, INC. produced more free cash flow last quarter ($1.5M vs $-15.8M). Over the past eight quarters, IT TECH PACKAGING, INC.'s revenue compounded faster (10.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
IT TECH PACKAGING, INC. is a paper manufacturing enterprise primarily operating in China. It produces and distributes a diverse portfolio of paper products including corrugated packaging paper, boxboard, and printing-use cultural paper, serving sectors such as consumer goods packaging, logistics, and commercial printing across its core market.
CTMX vs ITP — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $25.6M |
| Net Profit | $-154.0K | $-1.4M |
| Gross Margin | — | 7.9% |
| Operating Margin | -6.9% | -3.9% |
| Net Margin | -0.8% | -5.7% |
| Revenue YoY | -25.7% | 2.1% |
| Net Profit YoY | 97.6% | 26.6% |
| EPS (diluted) | — | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $25.6M | ||
| Q2 25 | $18.7M | $24.8M | ||
| Q1 25 | $50.9M | $10.9M | ||
| Q4 24 | $38.1M | $17.6M | ||
| Q3 24 | $33.4M | $25.1M | ||
| Q2 24 | $25.1M | $26.2M | ||
| Q1 24 | $41.5M | $6.9M | ||
| Q4 23 | $26.6M | $21.0M |
| Q3 25 | — | $-1.4M | ||
| Q2 25 | $-154.0K | $-2.0M | ||
| Q1 25 | $23.5M | $-3.5M | ||
| Q4 24 | $18.9M | $-4.0M | ||
| Q3 24 | $5.7M | $-2.0M | ||
| Q2 24 | $-6.5M | $-77.7K | ||
| Q1 24 | $13.8M | $-3.7M | ||
| Q4 23 | $837.0K | $-4.0M |
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 7.6% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 5.8% | ||
| Q4 23 | — | 1.2% |
| Q3 25 | — | -3.9% | ||
| Q2 25 | -6.9% | -7.1% | ||
| Q1 25 | 44.4% | -31.0% | ||
| Q4 24 | 46.4% | -21.5% | ||
| Q3 24 | 12.3% | -5.8% | ||
| Q2 24 | -33.7% | 2.1% | ||
| Q1 24 | 28.1% | -51.0% | ||
| Q4 23 | -2.3% | -18.1% |
| Q3 25 | — | -5.7% | ||
| Q2 25 | -0.8% | -7.9% | ||
| Q1 25 | 46.2% | -32.2% | ||
| Q4 24 | 49.6% | -22.9% | ||
| Q3 24 | 17.2% | -7.9% | ||
| Q2 24 | -26.0% | -0.3% | ||
| Q1 24 | 33.3% | -54.6% | ||
| Q4 23 | 3.1% | -19.0% |
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.35 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | — | $-0.37 | ||
| Q4 23 | — | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | $4.7M |
| Stockholders' EquityBook value | $119.9M | $152.0M |
| Total Assets | $175.1M | $175.7M |
| Debt / EquityLower = less leverage | — | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — | ||
| Q4 23 | $17.2M | — |
| Q3 25 | — | $4.7M | ||
| Q2 25 | — | $4.7M | ||
| Q1 25 | — | $4.7M | ||
| Q4 24 | — | $4.7M | ||
| Q3 24 | — | $8.9M | ||
| Q2 24 | — | $11.3M | ||
| Q1 24 | — | $11.4M | ||
| Q4 23 | — | $11.4M |
| Q3 25 | — | $152.0M | ||
| Q2 25 | $119.9M | $152.3M | ||
| Q1 25 | $25.0M | $152.8M | ||
| Q4 24 | $-456.0K | $156.1M | ||
| Q3 24 | $-23.5M | $164.3M | ||
| Q2 24 | $-31.2M | $163.5M | ||
| Q1 24 | $-31.7M | $164.3M | ||
| Q4 23 | $-47.4M | $168.3M |
| Q3 25 | — | $175.7M | ||
| Q2 25 | $175.1M | $175.2M | ||
| Q1 25 | $98.5M | $175.2M | ||
| Q4 24 | $120.5M | $177.5M | ||
| Q3 24 | $139.0M | $190.0M | ||
| Q2 24 | $159.2M | $191.4M | ||
| Q1 24 | $184.7M | $177.5M | ||
| Q4 23 | $201.8M | $194.7M |
| Q3 25 | — | 0.03× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | 0.05× | ||
| Q2 24 | — | 0.07× | ||
| Q1 24 | — | 0.07× | ||
| Q4 23 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $1.5M |
| Free Cash FlowOCF − Capex | $-15.8M | $1.5M |
| FCF MarginFCF / Revenue | -84.6% | 5.9% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $3.8M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $1.5M | ||
| Q2 25 | $-15.8M | $1.4M | ||
| Q1 25 | $-21.0M | $-2.5M | ||
| Q4 24 | $-19.9M | $3.5M | ||
| Q3 24 | $-20.7M | $1.5M | ||
| Q2 24 | $-19.5M | $721.9K | ||
| Q1 24 | $-26.0M | $624.4K | ||
| Q4 23 | $-22.0M | $5.4M |
| Q3 25 | — | $1.5M | ||
| Q2 25 | $-15.8M | $1.3M | ||
| Q1 25 | $-21.2M | $-2.5M | ||
| Q4 24 | $-20.0M | $3.5M | ||
| Q3 24 | $-20.7M | $1.2M | ||
| Q2 24 | $-19.6M | $668.3K | ||
| Q1 24 | $-26.2M | $615.4K | ||
| Q4 23 | $-22.2M | $-7.7M |
| Q3 25 | — | 5.9% | ||
| Q2 25 | -84.6% | 5.4% | ||
| Q1 25 | -41.6% | -22.8% | ||
| Q4 24 | -52.5% | 19.6% | ||
| Q3 24 | -62.1% | 4.9% | ||
| Q2 24 | -78.2% | 2.5% | ||
| Q1 24 | -63.1% | 9.0% | ||
| Q4 23 | -83.5% | -36.7% |
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 1.0% | ||
| Q2 24 | 0.4% | 0.2% | ||
| Q1 24 | 0.3% | 0.1% | ||
| Q4 23 | 1.0% | 62.4% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — | ||
| Q4 23 | -26.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
ITP
Segment breakdown not available.
